Hello Tomorrow San Francisco - The Future of Healthcare

Hello Tomorrow San Francisco’s ambition during the Future of Healthcare session is to highlight disruptive technologies that will shape the future of biomedicine.

Our goal is to inspire and encourage the next generation of change-makers, fostering interdisciplinary collaborations, to accelerate innovation in the field. At the same time, we want to take this opportunity to start the conversation about the ethical, legal, political and operational challenges we will have to address in the near future.

Join us on December 15th to hear inspiring talks, learn about the latest technologies in healthcare, new methodologies to improve patient care, and some of the most pressing challenges we have to tackle. Come and meet an amazing diversity of like-minded attendees who will shape the future of healthcare with you!

INFORMATION

What: The Future of Healthcare, co-organized by Hello Tomorrow San Francisco and the Office for Science and Technology of the French Embassy in the United States

When: December 15th, 5:00pm to 10:30pm

Where: The Fillmore Heritage Center

AGENDA

5:00PM: Mingle and have a drink in our beautiful jazz venue

5:30PM: Opening remarks from Emmanuel Lebrun-Damiens, Consul General of France in San Francisco

5:45PM: Keynotes from Aubrey de Grey on the science of ageing, Andy May on CRISPR/Cas9 and Jacques Mallet on gene therapy and the regulation of therapeutic transgenes

6:25PM: Panel on the legal and ethical issues related to gene editing and anti-ageing research, Moderated by Hank Greely

6:45PM: Fireside chat between Adham Adjahmi and Cynthia Franck on rare disease research and the importance of patient engagement

7:05PM: Keynote from Michel Maharbiz & 2nd Keynote TBD soon

7:45PM: Panel on the challenges related to the use of artificial organs and miniaturized implants to treat diseases, Moderated by Hank Greely

8:05PM: Presentation from Mitesh Rao on the adoption of these technologies by health systems and the accessibility for patients

8:25PM: Closing remarks

8:30PM — 10:30PM: Cocktail, awesome Buffet... and Live Music!

ABOUT THE SPEAKERS

Aubrey de Grey — Biomedical Gerontologist & Chief Science Officer, Sens Research Foundation: He is a biomedical gerontologist based Mountain View, California, USA, and is the Chief Science Officer of SENS Research Foundation, a California-based biomedical research charity that performs and funds laboratory research dedicated to combating the aging process.

Andrew May — Chief Scientific Officer, Caribou Biosciences: Andy leads the research and development team at Caribou Biosciences and has a background developing technologies and bringing innovative products from concept to commercialization. He is a co-founder of Intellia Therapeutics and before joining Caribou, Andy led development teams in sequencing, single-cell genomics and structural proteomics at Fluidigm Corporation.

Henry T. Greely — Director, Center for Law and the Biosciences, Stanford University: He is also: Professor (by courtesy) of Genetics, Stanford School of Medicine; Chair, Steering Committee of the Center for Biomedical Ethics; and Director, Stanford Program in Neuroscience and Society. Henry T. Greely (BA ’74) specializes in the ethical, legal, and social implications of new biomedical technologies, particularly those related to neuroscience, genetics, or stem cell research.

Jacques Mallet - Emeritus Director of Research at CNRS and Brain & Spinal Cord Institute (Paris), Adjunct Professor at UCSF: Jacques has been a leader in the gene therapy field for several decades. He notably pionered the field of brain molecular genetics and his work has produced breakthroughs in neuronal plasticity, psychiatric diseases, epigenetics, and neurodegenerative disorders. This year, he co-authored a Nature Biotechnology paper that describes an edible switch for gene therapy. This innovative approach which is particularly well suited for intermitent regulation of therapeutic transgenes over short and long period of time, has the potential to overcome a central challenge in the field of cellular and gene therapy.

Adham Aljahmi — Ceo & Co-Founder, Blue Turtle Bio Technologies: He is the CEO and co-founder of Blue Turtle Bio Technologies. Blue Turtle Bio Technologies, Inc. develops microbe based protein therapy for Gaucher’s disease.

Cynthia J. Frank — Gaucher and rare disease patient advocate: Cyndi is a Gaucher and rare disease patient advocate. She is a long-standing member of the Gaucher and rare disease communities and over a 40-year span has participated in many clinical trials and research studies to help bring treatments to market.

Mitesh B. Rao — System Patient Safety Officer, Stanford Healthcare: He is the System Patient Safety Officer for Stanford Healthcare where he leads Patient Safety for the Enterprise. Dr. Rao also serves as the founding Director of the Center for Advancing Patient Safety (CAPS), which focuses on advancing the science and implementing new innovations and technologies in the fields of Patient Safety and Quality Improvement.

Michel M. Maharbiz — Associate Professor with the Department of Electrical Engineering and computer science, University of California, Berkeley: He is an Associate Professor with the Department of Electrical Engineering and Computer Science at the University of California, Berkeley. Prof. Maharbiz is a Bakar Fellow and was the recipient of a 2009 NSF Career Award for research into developing microfabricated interfaces for synthetic biology.

--

Many thanks to our sponsors:

Bank of The West

L'Atelier BNP Paribas

Wilson Sonsini Goodrich & Rosati

And our local partners:

IndieBio

French Tech Hub

PRIME

French-American Chamber of Commerce San Francisco (FACCSF)